It's no secret that Novo Nordisk ( NVO -1.69%) and Eli Lilly ( LLY 1.57%) are toughing it out in the battle of the weight loss drug market. It's also not lost on many investors that Eli Lilly's obesity drug, Zepbound, is winning market share away from Novo Nordisk's offering, Wegovy.

Denmark's economy remains robust despite job cuts at Novo Nordisk , the finance minister told Reuters on Wednesday, dismissing concerns that the pharmaceutical company's financial troubles could further impact the country’s economic outlook.

Novo Nordisk is deeply undervalued despite stellar fundamentals: 18% sales growth, a 29% OP jump, and a rock-solid balance sheet. See why NVO stock is a buy.

Novo Nordisk’s popular weight loss drug, Wegovy, is the first and only GLP-1 medication approved to treat metabolic associated steatohepatitis, a serious condition marked by liver scarring. The FDA granted the approval Aug.